Slow granular that is, chronic granulocytic leukemia, taking imatinib platelet low considerations related to adverse drug reactions, the need to reduce the amount of drugs, stop the drug or change the drug treatment, at the same time can be given to the platelet transfusion and other supportive treatment. 1. If platelet reduction occurs when taking imatinib, the medication should be adjusted according to the specific platelet count, and the medication should be discontinued when the platelet count is <50×10^9/L, and resumed when the platelet is ≥75×10^9/L. If repeated episodes of platelet count <50 × 10^9/L should be discontinued, to be recovered to reduce the dosage. 2. If the adverse reaction of imatinib is severe, the treatment can be replaced with second-generation targeted drugs such as dasatinib. 3. If platelets are severely reduced, supportive therapy such as platelet transfusion can be given. Chronic granulocytic leukemia is often treated with tyrosine kinase inhibitors (such as imatinib), and 90% of patients with chronic granulocytic leukemia who are treated with these drugs can survive for a long time. Long-term use of imatinib often results in gastrointestinal reactions, liver injury, thrombocytopenia and other adverse reactions. Severe hepatic and renal impairment or allergic to the product patients are prohibited. Chronic granulocytic leukemia taking imatinib appear platelet low, it is recommended to standardize the treatment under the guidance of the doctor, so as not to delay the condition.